| 2023/02/03 08:01:08 | |
|---|---|
| Price | |
| 305.45 EUR | |
| Difference | -2.12% (-6.60) |
General attributes
| ISIN | US5324571083 |
| Symbol | LLY |
| Exchange | Hanover |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 310,121 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 305.45 EUR |
| High | 305.45 EUR |
| Low | 305.45 EUR |
| Close (prev. day) | 312.05 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 1 |
| Last size | 0 |
Futures and Options
| Related Futures | 15 |
| Related Options | - |
PDF Downloads
| Company report: ELI LILLY AND COMPANY |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2023/01/30 |
|
Global Equity Ratings |
|
| 2023/01/09 |
|
Global Equity Ratings |
|
| 2022/12/19 |
|
Global Equity Ratings |
|
| 2022/11/28 |
|
Global Equity Ratings |
|
| 2022/11/18 |
|
Global Equity Ratings |
|
| 2023/02/03 08:01:08 | |
|---|---|
| Price | |
| 305.45 EUR | |
| Difference | -2.12% (-6.60) |
General attributes
| ISIN | US5324571083 |
| Symbol | LLY |
| Exchange | Hanover |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 310,121 EUR |
| Benchmark | S&P 500 |
Market data
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | 305.45 EUR |
| High | 305.45 EUR |
| Low | 305.45 EUR |
| Close (prev. day) | 312.05 EUR |
| VWAP | - |
| Volume (pcs) | 0 |
| Trading volume | 0.00 |
| Number of trades | 1 |
| Last size | 0 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -2.88% | +38.53% | +141.73% |
| Perf (abs.) | -9.05 | +84.95 | +179.09 |
| Beta | 0.42 | 0.49 | 0.64 |
| Volatility | 31.23 | 30.71 | 35.96 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 312.47 EUR (0) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 329.24 EUR (0) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 338.89 EUR (1) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 305.97 EUR (1) |
| YTD High | date | 344.95 EUR (2023/01/04) |
| YTD Low | date | 305.45 EUR (2023/02/03) |
| 52 Weeks High | date | 371.50 EUR (2022/11/04) |
| 52 Weeks Low | date | 206.80 EUR (2022/02/14) |
All listings for ELI LILLY AND COMPANY
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Xetra | 2023/02/03 | 17:35 | 314.95 EUR | 0.92 | 101 |
| Vienna Stock Exchange | 2023/02/03 | 17:32 | 314.45 EUR | 0.00 | 1 |
| Tradegate | 2023/02/03 | 22:26 | 314.15 EUR | 0.73 | 131 |
| Stuttgart | 2023/02/03 | 16:11 | 310.80 EUR | 0.01 | 7 |
| SIX Swiss Exchange | 2023/02/03 | 17:35 | 310.00 CHF | 0.00 | 1 |
| NYSE | 2023/02/03 | 22:02 | 339.08 USD | 1,917.89 | 108,865 |
| Munich | 2023/02/03 | 18:30 | 314.65 EUR | 0.00 | 2 |
| London Stock Exchange | 2021/12/10 | 15:37 | 225.3104 CHF | 0.02 | 1 |
| Hanover | 2023/02/03 | 08:01 | 305.45 EUR | 0.00 | 1 |
| Hamburg | 2023/02/03 | 08:01 | 305.45 EUR | 0.00 | 1 |
| Frankfurt | 2023/02/03 | 17:27 | 315.30 EUR | 0.39 | 18 |
| Duesseldorf | 2023/02/03 | 21:01 | 311.15 EUR | 0.00 | 11 |
| Berlin | 2023/02/03 | 08:08 | 305.45 EUR | 0.00 | 1 |
| BX Swiss | 2023/02/02 | 18:00 | 289.858 CHF | 0.01 | 1 |
Company Logo
Contact Details
| ELI LILLY & CO. |
| - - |
| Lilly Corporate Center - 46285 Indianapolis |
| Telefon: 1-317-276-2000 |
| Fax: - |
| E-mail: communications_corporate@lilly.com |
PDF Downloads
| Company report: ELI LILLY AND COMPANY | |
Company Profile
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The firm's products consist of Diabetes, Oncology, Immunology, Neuroscience, and Other therapies. The Diabetes products include Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta, and Trulicity. The Oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. The Immunology products include Olumiant and Taltz. The Neuroscience products consist of Cymbalta, Emgality, Reyvow, and Zyprexa. The Other therapies include Bamlanivimab, Cialis, and Forteo. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN. |
Members of Management Board
| Katherine Baicker | Member of Board of Directors |
| Marschall Runge | Member of Board of Directors |
| Mary Lynne Hedley | Member of Board of Directors |
| William Kaelin | Member of Board of Directors |
| Gabrielle Greene-Sulzberger | Member of Board of Directors |
| Jackson Tai | Member of Board of Directors |
| Jamere Jackson | Member of Board of Directors |
| Jon Fyrwald | Member of Board of Directors |
| Juan Luciano | Member of Board of Directors |
| Karen Walker | Member of Board of Directors |
| Kimberly Johnson | Member of Board of Directors |
| Ralph Alvarez | Member of Board of Directors |
| David A. Ricks | Chairman of Managing Board |
| Daniel M. Skovronsky | Member of Executive Committee |
| Alfonso G. Zulueta | Member of Executive Committee |
| Alonzo Weems | Member of Executive Committee |
| Anat Ashkenazi | Member of Executive Committee |
| Anat Hakim | Member of Executive Committee |
| Anne E. White | Member of Executive Committee |
| Diogo Rau | Member of Executive Committee |
| Edgardo Hernandez | Member of Executive Committee |
| Ilya Yuffa | Member of Executive Committee |
| Jacob Van Naarden | Member of Executive Committee |
| Johna Norton | Member of Executive Committee |
| Leigh Ann Pusey | Member of Executive Committee |